Effects of α7 nicotinic acetylcholine receptor agonist against α-synuclein-induced neurotoxicity

被引：1

作者：

Takizawa, Shinnosuke ^{[1
]}

Ohuchi, Kazuki ^{[1
]}

Fujimaki, Ayaka ^{[1
]}

Ito, Taisei ^{[1
]}

Murakami, Takanori ^{[1
]}

Kurita, Hisaka ^{[1
]}

Inden, Masatoshi ^{[1
]}

机构：

[1] Gifu Pharmaceut Univ, Lab Med Therapeut & Mol Therapeut, 1-25-4 Daigaku Nishi, Gifu, Gifu 5011196, Japan

来源：

NEUROSCIENCE LETTERS | 2024年 / 823卷

基金：

日本学术振兴会;

关键词：

alpha 7 nicotinic acetylcholine receptor; Neuroprotection; Autophagy; MEDIATED NEUROPROTECTION;

D O I：

10.1016/j.neulet.2024.137654

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

The alpha 7 neuronal nicotinic acetylcholine receptor (alpha 7 nAChR) is a potential target for the development of Parkinson's disease (PD) therapeutics. alpha-Synuclein (alpha-Syn), a principal component of Lewy bodies (cytoplasmic inclusions), is a major contributor to PD pathophysiology. Previous studies have demonstrated that activating alpha 7 nAChR protects against nigrostriatal dopamine degeneration in acute and chronic PD animal models induced by 6-hydroxydopamine and rotenone, respectively. In the present study, we investigated the effects of PNU282987, a selective alpha 7 nAChR agonist, against alpha-Syn-induced neurotoxicity in alpha-Syn(WT)-, alpha-Syn(A30P)-, and alpha-Syn(E46K)-N2a cells. PNU282987 exhibited substantial neuroprotection against both wild-type and mutant-type alpha-Syn-induced toxicity. Furthermore, PNU282987 promoted transcription factor EB activity and reduced intracellular alpha-Syn protein levels through autophagy induction. These results highlight the therapeutic potential of alpha 7 nAChR activation in diseases characterized by alpha-Syn aggregation, such as PD.

引用

页数：6

共 50 条

[31] Molecular dissection of tropisetron, an α7 nicotinic acetylcholine receptor-selective partial agonist
Papke, RL
Schiff, HC
Jack, BA
Horenstein, NA
NEUROSCIENCE LETTERS, 2005, 378 (03) : 140 - 144
[32] Pilot study of an α7 nicotinic acetylcholine receptor agonist adjuvant therapeutic strategy for schizophrenia
Deutsch, Stephen I.
Schwartz, Barbara L.
Schooler, Nina R.
Rosse, Richard B.
Mastropaolo, John
Gaskins, Brooke L.
NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S250 - S250
[33] Alpha7 nicotinic acetylcholine receptor agonist improves survival during endotoxemia
Chen, F.
Cai, B.
Dong, W.
Deitch, E. A.
Ulloa, L.
SHOCK, 2008, 29 : 80 - 80
[34] APN1125: A clinical stage α7 nicotinic acetylcholine receptor partial agonist
Koelsch, Gerald
Detke, Michael J.
Stevens, Karen E.
Meltzer, Leonard T.
Terry, Alvin V., Jr.
Callahan, Patrick M.
Yoshimura, Ryan F.
Bilcer, Geoffrey
Anderson, Paul C.
Ng, John
Ng, Raymond
Kelly, Terence A.
BIOCHEMICAL PHARMACOLOGY, 2015, 97 (04) : 636 - 636
[35] Electrostatic effects on the association kinetics of agonist binding to nicotinic acetylcholine receptor (AChR).
Song, XZS
Pedersen, SE
BIOPHYSICAL JOURNAL, 2001, 80 (01) : 461A - 461A
[36] α7 Nicotinic Receptor Promotes the Neuroprotective Functions of Astrocytes against Oxaliplatin Neurotoxicity
Mannelli, Lorenzo Di Cesare
Tenci, Barbara
Zanardelli, Matteo
Failli, Paola
Ghelardini, Carla
NEURAL PLASTICITY, 2015, 2015
[37] DECAMETHONIUM IS A PARTIAL AGONIST AT THE NICOTINIC ACETYLCHOLINE-RECEPTOR
LIU, Y
DILGER, JP
SYNAPSE, 1993, 13 (01) : 57 - 62
[38] Agonist binding to the quinacrine locus on the nicotinic acetylcholine receptor
Arias, HR
FASEB JOURNAL, 1999, 13 (07): : A1405 - A1405
[39] AGONIST AND CHANNEL KINETICS OF THE NICOTINIC ACETYLCHOLINE-RECEPTOR
NELSON, D
SACHS, F
BIOPHYSICAL JOURNAL, 1982, 37 (02) : A321 - A321
[40] Development of an Efficient Synthesis of an Agonist of Acetylcholine Nicotinic Receptor
Hardouin, Christophe
Poixblanc, Aurelie
Bariere, Francois
Tamion, Rodolphe
Dubuffet, Thierry
Hervouet, Yvon
Mouchet, Patrick
ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2018, 22 (10) : 1419 - 1425

← 1 2 3 4 5 →